Profile data is unavailable for this security.
About the company
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
- Revenue in USD (TTM)14.43m
- Net income in USD-28.72m
- Incorporated2012
- Employees157.00
- LocationProQR Therapeutics NVZernikedreef 9LEIDEN 2333 CKNetherlandsNLD
- Phone+31 854894932
- Websitehttps://www.proqr.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Conduit Pharmaceuticals Inc | 0.00 | -2.42m | 132.89m | 7.00 | -- | -- | -- | -- | -0.0339 | -0.0339 | 0.00 | -0.042 | 0.00 | -- | -- | 0.00 | -97.97 | -- | -- | -- | -- | -- | -- | -- | -- | -25.68 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.69m | 133.21m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 137.38m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| FitLife Brands Inc | 58.51m | 7.30m | 137.40m | 37.00 | 20.20 | 4.68 | 18.54 | 2.35 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Mediwound Ltd | 19.85m | -12.75m | 139.07m | 100.00 | -- | 6.13 | -- | 7.01 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| ProQR Therapeutics NV | 14.43m | -28.72m | 142.72m | 157.00 | -- | 3.97 | -- | 9.89 | -0.3538 | -0.3538 | 0.1778 | 0.4423 | 0.0957 | -- | -- | 91,924.53 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 145.34m | 100.00 | -- | 5.23 | -- | 1.73 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Boundless Bio Inc | -100.00bn | -100.00bn | 145.99m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -21.32m | 147.00m | 5.00 | -- | 3.71 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 147.62m | 107.00 | -- | 0.6119 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| I-Mab ADR | 3.81m | -202.01m | 148.82m | 220.00 | -- | 0.6271 | -- | 39.06 | -2.43 | -2.43 | 0.0458 | 2.93 | 0.0083 | -- | -- | 17,318.04 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 149.27m | 135.00 | -- | 6.08 | -- | 8.47 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Puma Biotechnology Inc | 226.63m | 15.38m | 150.02m | 185.00 | 9.66 | 2.94 | 5.57 | 0.662 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Atossa Therapeutics Inc | 0.00 | -29.69m | 150.91m | 10.00 | -- | 1.76 | -- | -- | -0.2359 | -0.2359 | 0.00 | 0.6833 | 0.00 | -- | -- | 0.00 | -28.65 | -29.97 | -29.84 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
Data as of Jun 14 2024. Currency figures normalised to ProQR Therapeutics NV's reporting currency: US Dollar USD
20.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Privium Fund Management BVas of 31 Mar 2024 | 5.34m | 6.61% |
| Adage Capital Management LPas of 31 Mar 2024 | 3.63m | 4.49% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 2.88m | 3.57% |
| M28 Capital Management LPas of 31 Mar 2024 | 1.02m | 1.26% |
| DAFNA Capital Management LLCas of 31 Mar 2024 | 905.58k | 1.12% |
| De Grote Voskuil Capital BVas of 31 Dec 2022 | 740.00k | 0.92% |
| Macquarie Investment Management Business Trustas of 31 Mar 2024 | 620.00k | 0.77% |
| Ikarian Capital LLCas of 31 Mar 2024 | 483.58k | 0.60% |
| DWS Investments (UK) Ltd.as of 31 Mar 2024 | 385.15k | 0.48% |
| Millennium Management LLCas of 31 Mar 2024 | 328.99k | 0.41% |
More ▼
Data from 31 Dec 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
